CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Selecting a BTK Inhibitor for Mantle Cell Lymphoma

January 30th 2020

Updates in Management of Mantle Cell Lymphoma

January 30th 2020

CAR T-Cell Therapy Continues to Generate Positive Results in Hematologic Cancers

January 29th 2020

Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.

T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors

January 11th 2020

CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.

Dr. Wong on Investigational CAR T-Cell Products in Multiple Myeloma

January 3rd 2020

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

CAR T-Cell Therapy as an Outpatient Treatment Option

December 23rd 2019

Anticipation of ZUMA-7 Results

December 23rd 2019

Next-Generation CAR T Therapy

December 23rd 2019

Expanded Use of CAR T Therapy in Hematologic Malignancies

December 23rd 2019

The TRANSCEND-NHL-001 Trial

December 23rd 2019

CAR T Associated Cytokine Release Syndrome

December 23rd 2019

Real-World Data and CAR T Therapy

December 23rd 2019

CAR-T Therapy Treatment Variables

December 23rd 2019

High-Risk Lymphoma: The ZUMA-1 and SCHOLAR-1 Trials

December 23rd 2019

Adult ALL and Data from ZUMA-3

December 23rd 2019

CAR T-Cell Therapy: Relapsed/Refractory ALL

December 23rd 2019

Treating Common Toxicities From CAR T Therapy

December 23rd 2019

A Conversation on MRD in ALL

December 23rd 2019

CAR T-Cell Therapy in Pediatric ALL

December 23rd 2019

Understanding of MRD and CAR T-Cell Therapy in ALL Continues to Evolve

December 23rd 2019

Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.